Aptinyx Inc.
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase I clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc to develop a compound for the treatment of major depressive disorder. Aptinyx Inc. was founded in 2015 and is headquartered in Evanston, Illinois. Show More...
-
Website http://www.aptinyx.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 0.10 USD
-
Last Updated 29-12-2023
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Earnings Per Share USD -0.6 -1.25 -2.64 -1.71 -1.55 Dividends USD Payout Ratio % * Shares Mil 26.0 26.0 20.0 34.0 36.0 Book Value Per Share * USD 4.85 3.35 2.68 Free Cash Flow Per Share * USD -1.25 -1.54 Return on Assets % -83.01 -55.3 -42.13 -43.81 -41.29 Financial Leverage (Average) 1.04 1.05 1.04 Return on Equity % -97.23 -45.81 -43.09 Return on Invested Capital % -97.23 -45.81 -43.09 Interest Coverage Current Ratio 3.8 21.74 26.04 21.47 27.15 Quick Ratio 3.67 21.29 25.7 20.28 26.22 Debt/Equity